ATE404698T1 - Methode zur bestimmung der resistenz gegen medikamente - Google Patents

Methode zur bestimmung der resistenz gegen medikamente

Info

Publication number
ATE404698T1
ATE404698T1 AT01933853T AT01933853T ATE404698T1 AT E404698 T1 ATE404698 T1 AT E404698T1 AT 01933853 T AT01933853 T AT 01933853T AT 01933853 T AT01933853 T AT 01933853T AT E404698 T1 ATE404698 T1 AT E404698T1
Authority
AT
Austria
Prior art keywords
phenotype
drugs
patient
database
resistance
Prior art date
Application number
AT01933853T
Other languages
English (en)
Inventor
Brendan Larder
Stuart Bloor
Kurt Hertogs
Pascale Dehertogh
Rudy Mortier
Original Assignee
Virco Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virco Bvba filed Critical Virco Bvba
Application granted granted Critical
Publication of ATE404698T1 publication Critical patent/ATE404698T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/20—Heterogeneous data integration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Databases & Information Systems (AREA)
  • AIDS & HIV (AREA)
  • Bioethics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
AT01933853T 2000-04-18 2001-04-18 Methode zur bestimmung der resistenz gegen medikamente ATE404698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19760600P 2000-04-18 2000-04-18
US21321900P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
ATE404698T1 true ATE404698T1 (de) 2008-08-15

Family

ID=26892992

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08160749T ATE526423T1 (de) 2000-04-18 2001-04-18 Verfahren zum messen des medikamentenwiderstands gegen hcv
AT01933853T ATE404698T1 (de) 2000-04-18 2001-04-18 Methode zur bestimmung der resistenz gegen medikamente

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08160749T ATE526423T1 (de) 2000-04-18 2001-04-18 Verfahren zum messen des medikamentenwiderstands gegen hcv

Country Status (9)

Country Link
US (3) US7206699B2 (de)
EP (2) EP2011889B1 (de)
JP (1) JP5156163B2 (de)
AT (2) ATE526423T1 (de)
AU (1) AU2001260224A1 (de)
CA (1) CA2406140A1 (de)
DE (1) DE60135366D1 (de)
ES (2) ES2373488T3 (de)
WO (1) WO2001079540A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4248593A (en) * 1992-05-14 1993-12-13 Mark Holodniy Polymerase chain reaction assays for monitoring antiviral therapy
US6968375B1 (en) * 1997-03-28 2005-11-22 Health Hero Network, Inc. Networked system for interactive communication and remote monitoring of individuals
US20040072722A1 (en) 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
US20040023375A1 (en) 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
EP1356082A2 (de) 2000-10-20 2003-10-29 Virco Bvba Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-reverse-transkriptase
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
WO2003040390A2 (en) 2001-11-08 2003-05-15 Tibotec Pharmaceuticals Ltd. Protease assay for therapeutic drug monitoring
EP1448987A4 (de) * 2001-12-10 2005-06-08 Ardais Corp Systeme und verfahren zur gewinnung von datenkorrelierten patientenproben
JP4041842B2 (ja) * 2002-01-15 2008-02-06 デジタル・インフォメーション・テクノロジー株式会社 Ｓｎｐ特定方法
ES2346717T3 (es) * 2002-03-11 2010-10-19 Lab 21 Limited Metodo y composiciones para identificar y caracterizar la hepatitis c.
DE60321466D1 (de) 2002-07-01 2008-07-17 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
EP1520247B1 (de) * 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
US8463441B2 (en) 2002-12-09 2013-06-11 Hudson Technologies, Inc. Method and apparatus for optimizing refrigeration systems
JP5348840B2 (ja) * 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
US8688385B2 (en) * 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
DE10324045B3 (de) * 2003-05-27 2004-10-14 Siemens Ag Verfahren sowie Computerprogramm mit Programmcode-Mitteln und Computerprogramm-Produkt zur Ermittlung eines zukünftigen Systemverhaltens eines dynamischen Systems
AU2004248290B2 (en) * 2003-06-10 2011-03-17 Virco Bvba Computational method for predicting the contribution of mutations to the drug resistance phenotype exhibited by HIV based on a linear regression anyalysis of the log fold resistance
US7939310B2 (en) * 2003-08-06 2011-05-10 University Of Massachusetts Systems and methods for analyzing nucleic acid sequences
CA2557790A1 (en) * 2004-03-02 2005-09-15 Virco Bvba Estimation of clinical cut-offs
JP2009517186A (ja) * 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化
JP5297814B2 (ja) * 2006-02-03 2013-09-25 ビルコ・ビーブイビーエイ 量的ｈｉｖ表現型又は向性アッセイ
US20070265658A1 (en) * 2006-05-12 2007-11-15 Aga Medical Corporation Anchoring and tethering system
EP2126137B1 (de) 2007-01-23 2017-06-07 Janssen Pharmaceutica NV Verfahren zur erstellung eines arzneimittelplans für hiv-infizierte patienten
US8617816B2 (en) * 2007-03-16 2013-12-31 454 Life Sciences, A Roche Company System and method for detection of HIV drug resistant variants
US20080293050A1 (en) * 2007-05-25 2008-11-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Gene analysis for determination of a treatment characteristic
CA2688278A1 (en) 2007-05-25 2008-12-04 Tibotec Pharmaceuticals New mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance
US8793074B2 (en) * 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
US7888034B2 (en) * 2008-07-01 2011-02-15 454 Life Sciences Corporation System and method for detection of HIV tropism variants
US8296686B1 (en) 2008-10-14 2012-10-23 Handhold Adaptive, LLC Portable prompting aid for the developmentally disabled
EP2534594B1 (de) 2010-02-12 2018-04-11 Janssen Sciences Ireland UC Berechnung der kombinierten stärke von arzneimitteldosierungen aus angepassten oder in-vitro-bestimmten dosisreaktionskurven
JP5984822B2 (ja) 2010-10-21 2016-09-06 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 注意欠陥多動性障害を有する患者を処置するための薬物を選択する方法
US8744982B2 (en) 2011-05-12 2014-06-03 University Of Utah Research Foundation Gene-specific prediction
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (de) 2011-10-21 2013-07-03 Abbvie Inc. Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2788490A1 (de) * 2011-12-05 2014-10-15 Duke University Identifizierung und klonen von übertragenen hepatitic-c-virus (hcv)-genomen durch einzelgenomamplifikation
US10679726B2 (en) 2012-11-26 2020-06-09 Koninklijke Philips N.V. Diagnostic genetic analysis using variant-disease association with patient-specific relevance assessment
WO2014110172A1 (en) * 2013-01-08 2014-07-17 Life Technologies Corporation Methods and systems for determining meta-genotypes
JP2016515378A (ja) * 2013-03-15 2016-05-30 ラボラトリー コーポレイション オブ アメリカ ホールディングス ウイルス阻害剤に対するウイルス感受性を決定するための方法
HK1221053A1 (zh) * 2013-05-23 2017-05-19 艾弗诺泰普有限责任公司 用於保持或改善健康的方法和系统
US10144976B2 (en) 2014-05-22 2018-12-04 Case Western Reserve University HIV-1 genotyping and coreceptor tropism assay
WO2017012659A1 (en) * 2015-07-22 2017-01-26 Curetis Gmbh Genetic testing for predicting resistance of salmonella species against antimicrobial agents
WO2017016602A1 (en) * 2015-07-29 2017-02-02 Curetis Gmbh Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2019055874A1 (en) * 2017-09-14 2019-03-21 uBiome, Inc. SIGNIFICANT INDEX MEASUREMENTS RELATING TO A MICROORGANISM

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6350311Y2 (de) 1984-11-16 1988-12-23
US5202259A (en) * 1986-05-20 1993-04-13 The Trustees Of Columbia University In The City Of New York Expression of human immunodeficiency virus (HIV) reverse transcriptase
HU219767B (hu) 1993-01-26 2001-07-30 Leslie R. Coney Készítmények és eljárások genetikai anyag sejtbe történő beviteléhez
KR100495690B1 (ko) * 1996-01-26 2005-11-08 비르코 비브이비에이 인체 hiv 계통의 표현형적 약제 감수성에 기초한 하나 이상의 최적한 hiv 저해제를 선발하는 방법
BR9704637A (pt) 1996-01-26 1998-06-09 Innogenetics Nv Processo para deteção de mutações induzidas por droga no gene de transcrição reversa
EP1053358A4 (de) 1998-02-10 2002-08-14 Uab Research Foundation Verwendung von hiv-1 integrase beim screening von potentiellen hiv-1 arzneistoffen
NZ508834A (en) 1998-05-26 2004-06-25 Virologic Inc Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
BR9912209A (pt) 1998-06-24 2002-11-05 Virologic Inc Recursos e métodos para monitoração de terapia anti-retroviral inibidora de transcriptase reversa de nucleosìdeo e guia de decisões terapêuticas no tratamento de hiv/aids
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
US6869759B1 (en) * 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU5758200A (en) 1999-06-22 2001-01-09 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
WO2001016860A2 (en) * 1999-08-27 2001-03-08 Iris Bio Technologies, Inc. Artificial intelligence system for genetic analysis
WO2001057245A2 (en) 2000-02-04 2001-08-09 K.U.Leuven Research & Development Hiv-1 resistance assay
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network

Also Published As

Publication number Publication date
ES2312436T3 (es) 2009-03-01
JP2004500836A (ja) 2004-01-15
AU2001260224A1 (en) 2001-10-30
WO2001079540A3 (en) 2003-06-05
ES2373488T3 (es) 2012-02-06
DE60135366D1 (de) 2008-09-25
US7206699B2 (en) 2007-04-17
EP2011889B1 (de) 2011-09-28
JP5156163B2 (ja) 2013-03-06
US20020091664A1 (en) 2002-07-11
US20040137436A1 (en) 2004-07-15
EP1332231B1 (de) 2008-08-13
WO2001079540A2 (en) 2001-10-25
EP1332231A2 (de) 2003-08-06
EP2011889A1 (de) 2009-01-07
CA2406140A1 (en) 2001-10-25
ATE526423T1 (de) 2011-10-15
US20070166747A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
ATE404698T1 (de) Methode zur bestimmung der resistenz gegen medikamente
Li et al. The validity of serum markers for fibrosis staging in chronic hepatitis B and C
Howell et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI
Liu et al. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy
Stader et al. Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving drug exposure changes in the elderly
AU784645B2 (en) Method for providing clinical diagnostic services
Kaszubinski et al. Dysbiosis in the dead: human postmortem microbiome beta-dispersion as an indicator of manner and cause of death
Dong et al. A risk score model for the prediction of osteosarcoma metastasis
Perera et al. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia
WO2000055624A3 (en) Elisa kit for the determination of metabolic phenotypes
Kazmers et al. Familial clustering of erosive hand osteoarthritis in a large statewide cohort
Yamashita et al. aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C
Kos et al. Common biological networks underlie genetic risk for alcoholism in African‐and European‐American populations
Mahajan et al. Association of Hepatitis B Surface Antigen Levels With Long‐Term Complications in Chronic Hepatitis B Virus Infection: A Systematic Literature Review
Wang et al. Circulating Mitochondrial DNA Content Associated with the Risk of Liver Cirrhosis: A Nested Case–Control Study
Andrews et al. The role of genomic‐informed risk assessments in predicting dementia outcomes
Hosaka et al. Development of HCC in patients receiving adefovir dipivoxil for lamivudine‐resistant hepatitis B virus mutants
WO2004111907A3 (en) Computational method for predicting the contribution of mutations to the drug resistance phenotype exhibited by hiv based on a linear regression analysis of the log fold resistance
CN110257518A (zh) 一种用于预测转移性结直肠癌转化治疗疗效的基因集
He et al. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation
Banks et al. Polycyclic aromatic hydrocarbons
Hawkes et al. A clinically meaningful difference was generated for a performance measure of recovery from hip fracture
CN113362956B (zh) 基于个体化代谢模型的肿瘤分型与潜在靶标预测方法
AU2003276727A8 (en) Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes
Crowe Jr Genetic predisposition for adverse events after vaccination

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1332231

Country of ref document: EP